JP2024545074A5 - - Google Patents

Info

Publication number
JP2024545074A5
JP2024545074A5 JP2024533796A JP2024533796A JP2024545074A5 JP 2024545074 A5 JP2024545074 A5 JP 2024545074A5 JP 2024533796 A JP2024533796 A JP 2024533796A JP 2024533796 A JP2024533796 A JP 2024533796A JP 2024545074 A5 JP2024545074 A5 JP 2024545074A5
Authority
JP
Japan
Prior art keywords
phosphodiesterase
modulator compound
pharmaceutically acceptable
use according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545074A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/FI2022/050813 external-priority patent/WO2023105119A1/en
Publication of JP2024545074A publication Critical patent/JP2024545074A/ja
Publication of JP2024545074A5 publication Critical patent/JP2024545074A5/ja
Pending legal-status Critical Current

Links

JP2024533796A 2021-12-07 2022-12-07 癌の処置における使用のための相乗効果のある組成物 Pending JP2024545074A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20216252 2021-12-07
FI20216252 2021-12-07
PCT/FI2022/050813 WO2023105119A1 (en) 2021-12-07 2022-12-07 Synergistic compositions for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024545074A JP2024545074A (ja) 2024-12-05
JP2024545074A5 true JP2024545074A5 (https=) 2025-10-24

Family

ID=84537056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533796A Pending JP2024545074A (ja) 2021-12-07 2022-12-07 癌の処置における使用のための相乗効果のある組成物

Country Status (6)

Country Link
US (1) US20250041294A1 (https=)
EP (1) EP4444314A1 (https=)
JP (1) JP2024545074A (https=)
CN (1) CN118354773A (https=)
CA (1) CA3239568A1 (https=)
WO (1) WO2023105119A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119970700A (zh) * 2025-03-05 2025-05-13 徐州医科大学 Lmk235在制备用于治疗慢性尿路感染药物中的应用
CN121081482B (zh) * 2025-11-10 2026-03-17 哈尔滨医科大学 Dnttip1基因在制备急性白血病治疗药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098137A1 (en) * 2006-04-05 2009-04-16 Novartis Ag Combinations of therapeutic agents for treating cancer
PT3052485T (pt) * 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
WO2015055898A2 (en) 2013-10-17 2015-04-23 Sihto Harri Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient
US11971402B2 (en) * 2015-04-24 2024-04-30 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
WO2017053823A1 (en) * 2015-09-25 2017-03-30 Pharmacyclics Llc Treatment using hdac inhibitors and immunotherapy
WO2017087947A2 (en) * 2015-11-19 2017-05-26 Pharmacyclics Llc Method of treatment of follicular lymphoma with a btk inhibitor
US10966986B2 (en) * 2016-02-05 2021-04-06 Bayer Pharma Aktiengesellschaft Compounds, compositions and methods for cancer patient stratification and cancer treatment
TWI808055B (zh) * 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018141835A1 (en) * 2017-02-03 2018-08-09 The Broad Institute, Inc. Compounds, compositions and methods for cancer treatment
US11191767B2 (en) * 2017-11-15 2021-12-07 Boris Slavinovich FARBER Pharmaceutical composition for stimulating stem cell division and suppressing bacterial virulence
CN112402613A (zh) * 2019-08-23 2021-02-26 中国科学院上海药物研究所 Pde3抑制剂与细胞因子联合治疗肿瘤的应用
US20220339257A1 (en) * 2019-09-18 2022-10-27 Biomarker Strategies, Llc Methods to increase the sensitivity and reversing the resistance to drugs
GB201916906D0 (en) * 2019-11-20 2020-01-01 Bailey David Stanley Combination therapies
TR202002067A2 (tr) * 2020-02-11 2021-08-23 Bahcesehir Ueniversitesi Bcl-2 i̇nhi̇bi̇törü olarak kullanilan yeni̇ küçük terapöti̇k bi̇leşi̇kleri̇n fi̇zi̇k odakli olarak keşfi̇
KR102643239B1 (ko) * 2020-03-11 2024-03-05 사회복지법인 삼성생명공익재단 포스포디에스터레이즈 5 억제제를 포함하는, nk-t 세포 림프종 또는 nk 세포 백혈병 예방 또는 치료용 약학적 조성물

Similar Documents

Publication Publication Date Title
Shafer et al. Update on rational targeted therapy in AML
RU2407532C9 (ru) Комбинации, предназначенные для лечения заболеваний, включающих пролиферацию клеток
JP2022166188A5 (https=)
JP2024545074A5 (https=)
KR20240097966A (ko) 암을 치료하는 방법
JP2017523206A (ja) ブルトン型チロシンキナーゼ阻害剤の新規製剤
JP6716585B2 (ja) 結腸直腸癌の処置に使用するためのアピリモド
AU2024323620A1 (en) Crystalline forms of a pi3k inhibitor and uses of same
CA2861056A1 (en) Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders
EP3823628A1 (en) <smallcaps/>? ? ?s? ? ? ? ?certain (2)- <ns1:i>n</ns1:i>?-[(1 <ns2:i>s</ns2:i>?)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
CA2891300A1 (en) Inhibition of drug resistant cancer cells
JP2025041656A (ja) がんの治療のための方法および組成物
JPWO2004066998A1 (ja) 安定な経口用固形医薬組成物
JP5948332B2 (ja) Ｍｌｌ再構成白血病の治療法
JP2022521407A5 (https=)
CN1387434A (zh) Nk1受体拮抗剂及gaba结构类似物的协同组合
AU2008309562B2 (en) Isoxazole compound for the treatment of cancer
US20130085115A1 (en) Combination therapy for lymphoma
Su et al. The clinical pharmacology and toxicity profile of rapalogs
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
US9526714B2 (en) Method for treating skin lesions with ingenol mebutate
JP2013508458A5 (https=)
RU2290931C2 (ru) Лекарственное средство, снижающее микробную обсемененность helicobacter pylori у пациентов с язвенной болезнью двенадцатиперстной кишки в сочетании с описторхозом
KR101944124B1 (ko) 약학 조성물
AU2015218471A1 (en) Inhibition of drug resistant cancer cells